TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Nona Biosciences Collaborates with Boostimmune to Advance Antibody-Drug Conjugate Development

Tuesday, February 27, 2024

Nona Biosciences, a subsidiary of HBM Holdings Limited dedicated to pioneering technological advancements and offering end-to-end solutions from conception to regulatory approval, has announced a collaboration agreement with Boostimmune, a biotech firm focused on advancing immune-modulating therapies for cancer treatment. The partnership aims to harness Nona's proprietary Harbour Mice® H2L2 platform, which incorporates two light and two heavy chains, to fast-track the development of Antibody-Drug Conjugates (ADCs) targeting novel cancer-related molecules.

Nona Biosciences, emphasized, "Through leveraging our extensive expertise in ADC discovery and utilizing our globally validated therapeutic antibody platforms, this collaboration is poised to expedite the creation of groundbreaking ADCs aimed at combating cancer. Teaming up with Boostimmune, we anticipate delivering revolutionary treatments that will significantly enhance patient outcomes."

Boostimmune, expressed enthusiasm, saying, "We are thrilled to join forces with Nona Biosciences. By aligning our strategic resources and expertise, we aim to accelerate the development of ADC therapies targeting previously unexplored cancer markers. Together, we are confident in our ability to make substantial progress in meeting the unmet needs of cancer patients."



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit